Literature DB >> 15196716

GnRH antagonists.

Maria Elisabetta Coccia1, Ciro Comparetto, Gian Luca Bracco, Gianfranco Scarselli.   

Abstract

Ovarian stimulation is an important step in the success rate of in vitro fertilization (IVF) allowing multiple follicular growth, several oocytes and consequently more embryos. The combination of GnRH-antagonists (GnRH-ant) and gonadotrophins is now available for clinical use and represent a valid alternative to classical protocol with GnRH agonist. GnRH-antagonists induce a direct block of GnRH receptor with a rapid decrease in LH and FSH, preventing LH surge. Two protocols has been designed for assisted reproduction technology (ART) treatment: multiple-dose protocol and a single-dose. Both protocols are simply, efficacious, started in the late follicular phase and do not have side effects. A review of GnRH-antagonist applications in ART cycles are presented. Smaller doses of gonadotrophins, shorter stimulation period and lower ovarian hyperstimulation syndrome (OHSS) incidence are reported in literature using GnRH-antagonist compared to agonist. Triggering of ovulation, the use in polycystic ovarian syndrome (PCOS) and poor reponders patients are other interesting indication. Regarding to pregnancy rate and potentially adverse effects of drugs on endometrium or implantation needed more data.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196716     DOI: 10.1016/j.ejogrb.2004.01.033

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

Review 1.  The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.

Authors:  Anna M Barron; Giuseppe Verdile; Ralph N Martins
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

2.  GnRH antagonists may affect endometrial receptivity.

Authors:  Beth W Rackow; Harvey J Kliman; Hugh S Taylor
Journal:  Fertil Steril       Date:  2008-04-14       Impact factor: 7.329

3.  Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.

Authors:  Wolfgang Koechling; Rolf Hjortkjaer; László B Tankó
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 4.  GnRH pulsatility, the pituitary response and reproductive dysfunction.

Authors:  Rie Tsutsumi; Nicholas J G Webster
Journal:  Endocr J       Date:  2009-07-17       Impact factor: 2.349

5.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

6.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

7.  Cost-effectiveness analysis of GnRH-agonist long-protocol and GnRH-antagonist protocol for in vitro fertilization.

Authors:  Miaomiao Jing; Chenxi Lin; Wenjun Zhu; Xiaoyu Tu; Qi Chen; Xiufang Wang; Youbing Zheng; Runju Zhang
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

8.  Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol.

Authors:  Maryam Eftekhar; Razieh Dehghani Firouzabadi; Hesamoddin Karimi; Elham Rahmani
Journal:  Iran J Reprod Med       Date:  2012-07

9.  Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis.

Authors:  Ruolin Wang; Shouren Lin; Yong Wang; Weiping Qian; Liang Zhou
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.